Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Aug 14

PMID 26270691

Citations 177

Authors

Colleen F Kelley

Erin Kahle

Aaron Siegler

Travis Sanchez

Carlos Del Rio

Patrick S Sullivan

Eli S Rosenberg

Affiliations

Soon will be listed here.

Abstract

Reductions in human immunodeficiency virus (HIV) incidence with pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) will require significant coverage of those at risk. We propose a simplified framework, similar to the HIV care continuum, to achieve protection with PrEP as follows: 1. At-risk MSM; 2. Awareness of and willingness to take PrEP; 3. Access to healthcare; 4. Receiving a prescription; and 5. Adhering to effective PrEP. We evaluated the PrEP care continuum on an Atlanta cohort of MSM and projected how many MSM might achieve protection from HIV. Even with optimistic estimates, few Atlanta MSM (15%) are projected to achieve protection from HIV with PrEP given the significant barriers described. Each continuum step represents an important point for intervention that could substantially increase the overall effectiveness of PrEP. In addition, novel strategies for PrEP delivery are needed to achieve the necessary effectiveness for Atlanta MSM at risk of HIV.

Citing Articles

Gay and bisexual adolescents and other men who have sex with men: intersectionality and the PrEP care continuum.

Oliveira E, Santos L, Zucchi E, Massa P, Grangeiro A, Couto M Rev Saude Publica. 2024; 58(suppl 1):11s.

PMID: 39417507 PMC: 11573366. DOI: 10.11606/s1518-8787.2024058005705.

Exploring Effects of Race and Differential Item Functioning on PrEP Stigma Experiences: Implications for Latent Stigma Measurement in Racially and Sexually Diverse Populations.

Maragh-Bass A, Siegler A, Mayer K, Dulin A, Sales J, Stegmueller D AIDS Behav. 2024; 28(12):4005-4019.

PMID: 39352601 PMC: 11588521. DOI: 10.1007/s10461-024-04499-5.

A Systematic Review and Narrative Synthesis of Factors Affecting Pre-exposure Prophylaxis Willingness Among Black Women for HIV Prevention.

Sims Haynes A, Markham C, Schick V, Suchting R, Parthasarathy N, Choudhury S AIDS Behav. 2024; 29(1):101-132.

PMID: 39340583 PMC: 11739211. DOI: 10.1007/s10461-024-04491-z.

Role of the pharmacist caring for people at risk of or living with HIV in Canada.

Tkachuk S, Ready E, Chan S, Hawkes J, Janzen Cheney T, Kapler J Can Pharm J (Ott). 2024; 157(5):218-239.

PMID: 39310805 PMC: 11412478. DOI: 10.1177/17151635241267350.

Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States.

Gordon A, Haiken S, Murchison G, Agenor M, Hughto J, Nelson K Qual Health Res. 2024; 35(1):74-87.

PMID: 39095331 PMC: 11869390. DOI: 10.1177/10497323241265943.

References

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence --- 24 cities, United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2011; 60(31):1045-9. View

Gomez G, Borquez A, Case K, Wheelock A, Vassall A, Hankins C . The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013; 10(3):e1001401. PMC: 3595225. DOI: 10.1371/journal.pmed.1001401. View

Golub S, Gamarel K, Rendina H, Surace A, Lelutiu-Weinberger C . From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013; 27(4):248-54. PMC: 3624632. DOI: 10.1089/apc.2012.0419. View

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

Young I, McDaid L . How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2013; 18(2):195-216. PMC: 3905168. DOI: 10.1007/s10461-013-0560-7. View

Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D . Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014; 11(3):e1001613. PMC: 3942317. DOI: 10.1371/journal.pmed.1001613. View

Sullivan P, Peterson J, Rosenberg E, Kelley C, Cooper H, Vaughan A . Understanding racial HIV/STI disparities in black and white men who have sex with men: a multilevel approach. PLoS One. 2014; 9(3):e90514. PMC: 3946498. DOI: 10.1371/journal.pone.0090514. View

Bauermeister J, Meanley S, Pingel E, Soler J, Harper G . PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res. 2014; 11(7):520-7. PMC: 4152728. DOI: 10.2174/1570162x12666140129100411. View

10.

McNairy M, El-Sadr W . A paradigm shift: focus on the HIV prevention continuum. Clin Infect Dis. 2014; 59 Suppl 1:S12-5. PMC: 4141493. DOI: 10.1093/cid/ciu251. View

11.

King H, Keller S, Giancola M, Rodriguez D, Chau J, Young J . Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav. 2014; 18(9):1722-5. PMC: 4127131. DOI: 10.1007/s10461-014-0845-5. View

12.

Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

13.

Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

14.

Sowicz T, Teitelman A, Coleman C, Brawner B . Considerations for implementing oral preexposure prophylaxis: a literature review. J Assoc Nurses AIDS Care. 2014; 25(6):496-507. DOI: 10.1016/j.jana.2014.07.005. View

15.

Wall K, Khosropour C, Sullivan P . Offering of HIV screening to men who have sex with men by their health care providers and associated factors. J Int Assoc Physicians AIDS Care (Chic). 2010; 9(5):284-8. PMC: 3637046. DOI: 10.1177/1545109710379051. View

16.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

17.

Radzio J, Spreen W, Yueh Y, Mitchell J, Jenkins L, Garcia-Lerma J . The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015; 7(270):270ra5. DOI: 10.1126/scitranslmed.3010297. View

18.

Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K . Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. AIDS Behav. 2015; 19(5):802-10. PMC: 4417031. DOI: 10.1007/s10461-015-0996-z. View

19.

Gardner E, McLees M, Steiner J, Del Rio C, Burman W . The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011; 52(6):793-800. PMC: 3106261. DOI: 10.1093/cid/ciq243. View

20.

Anderson P, Glidden D, Liu A, Buchbinder S, Lama J, Guanira J . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra125. PMC: 3721979. DOI: 10.1126/scitranslmed.3004006. View